|
Cell treatment | Ischemic model | Outcomes | References |
|
Ex vivo culture expanded human EPCs from healthy young individuals | Myocardial ischemia in athymic nude mice | Increased neovascularization; increased capillary density; reduced infarct size; improved LV function after myocardial ischemia | [25] |
Human peripheral blood MNC-derived CD14+ or CD14− EPCs | Hindlimb ischemia in athymic nude mice | Increased blood perfusion; increased capillary density | [26] |
Human blood-derived CD34+ cells | Hindlimb ischemia in diabetic mice | Increased blood flow perfusion in diabetic mice, but not in nondiabetic mice | [27] |
Human blood cord-derived CD34+ EPCs | Cerebral ischemia in mice | Accelerated neovascularization of infarct neuronal tissue; increased cortical expansion; increased neuronal regeneration; improved recovery of motor deficits | [28] |
Ex vivo expanded human EPCs from peripheral blood followed by VEGF transduction | Hindlimb ischemia in athymic nude mice | Reduced limb loss; increased blood flow recovery after ischemia; increased EPC incorporation in vivo | [29] |
Autologous EPCs from peripheral blood | Pulmonary hypertension in dogs | Improved pulmonary artery pressure, cardiac output, and pulmonary vascular resistance | [30] |
Autologous EPCs from peripheral blood | Carotid denudation in rabbits | Accelerated reendothelialization; improved endothelial function | [31] |
Autologous CD34+ EPCs from bone marrow | Acute myocardial infarction in macaques | Improved regional blood flow; increased capillary density in the peri-infarct region; improved cardiac function; increased VEGF and bFGF levels in peri-infarct region | [32] |
|